| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
|
N Engl J Med
|
2012
|
9.69
|
|
2
|
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.
|
N Engl J Med
|
2010
|
8.77
|
|
3
|
Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.
|
J Clin Oncol
|
2013
|
1.70
|
|
4
|
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.
|
Haematologica
|
2013
|
1.67
|
|
5
|
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts.
|
J Hematol Oncol
|
2013
|
1.05
|
|
6
|
DPC 817: a cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variants.
|
Antimicrob Agents Chemother
|
2002
|
1.01
|
|
7
|
Progressive burden of myelofibrosis in untreated patients: assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study.
|
Leuk Res
|
2013
|
1.00
|
|
8
|
HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).
|
Antivir Chem Chemother
|
2003
|
0.98
|
|
9
|
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis.
|
Br J Haematol
|
2013
|
0.95
|
|
10
|
Identification and characterization of INCB9471, an allosteric noncompetitive small-molecule antagonist of C-C chemokine receptor 5 with potent inhibitory activity against monocyte migration and HIV-1 infection.
|
J Pharmacol Exp Ther
|
2011
|
0.82
|
|
11
|
P1 Phenethyl peptide boronic acid inhibitors of HCV NS3 protease.
|
Bioorg Med Chem Lett
|
2002
|
0.79
|
|
12
|
N4-acyl-modified D-2',3'-dideoxy-5-fluorocytidine nucleoside analogues with improved antiviral activity.
|
Antivir Chem Chemother
|
2003
|
0.77
|
|
13
|
Synthesis, antiviral activity and pharmacokinetics of P1/P1' substituted 3-aminoindazole cyclic urea HIV protease inhibitors.
|
Bioorg Med Chem Lett
|
2003
|
0.75
|